PASG

Passage BIO is a clinical-stage genetic-medicines company with zero product revenue in any year on record (FY2021–FY2025) and an accumulated deficit of $704.8M. The 'improving' loss trend — net loss narrowing from -$185M (FY2021) to -$45.5M (FY2025), with R&D cut 42.1% to $23.3M — is not a sign of a maturing business; it is a company shrinking itself. The 10-K confirms this: it terminated all discovery and exploratory research with Penn, gave up eight future CNS options, and outlicensed GM1/Krabbe/MLD to Gemma, which now carries the Penn payments. What's left is a residual pipeline (FTD and licensed assets) inside a corporate structure that is contracting, not scaling.

The balance sheet frames a hard near-term catch. Cash is $46.3M, but MD&A explicitly states this only funds operations 'through the end of the first quarter of 2027' — roughly three quarters from today — against operating cash burn of -$31.5M. Management concedes it 'will need to raise substantial additional capital' via equity, debt, or 'other strategic transactions,' with 'no assurances' of success. Stockholders' equity collapsed 69.4% to $18.8M, liabilities/equity sits at 2.32x, and ROE is -242.7%. The 94.8% drop in shares outstanding to 3.21M is a reverse split — the classic listing-preservation move of a broken micro-cap, not a buyback.